Primary Treatment of Prostatic Carcinoma with Estramustine Phosphate: Preliminary Report
- 1 February 1976
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 115 (2), 168-169
- https://doi.org/10.1016/s0022-5347(17)59119-3
Abstract
Estramustine phosphate has been used as primary treatment in 38 patients with advanced prostatic carcinoma. Of these 38 patients 36 responded objectively to treatment, regression occurring in 10 patients with soft tissue metastases, 3 with pulmonary metastases and 3 with bony metastases. Primary cytotoxic treatment in patients with far advanced prostatic carcinoma is advocated and a randomized clinical study is suggested.Keywords
This publication has 6 references indexed in Scilit:
- Stage D prostatic carcinoma Survival rate in relapsed patients following new forms of palliationUrology, 1974
- Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical StagingJournal of Urology, 1974
- Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinomaCancer, 1973
- Treatment of Advanced Prostatic Carcinoma with Estracyt: A Preliminary ReportScandinavian Journal of Urology and Nephrology, 1971
- Use of Teiethylene Thio-phosphoramide (thio-TEPA) in Treatment of Advanced Carcinoma of ProstateJournal of Urology, 1959
- Organspezifische Chemotherapie des Krebs. (Prostata-Karzinom)Klinische Wochenschrift, 1952